247 related articles for article (PubMed ID: 35192544)
21. Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects.
Kujawski M; Zhang C; Herrmann A; Reckamp K; Scuto A; Jensen M; Deng J; Forman S; Figlin R; Yu H
Cancer Res; 2010 Dec; 70(23):9599-610. PubMed ID: 21118964
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma.
Fujita M; Zhu X; Sasaki K; Ueda R; Low KL; Pollack IF; Okada H
J Immunol; 2008 Feb; 180(4):2089-98. PubMed ID: 18250414
[TBL] [Abstract][Full Text] [Related]
23. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
[TBL] [Abstract][Full Text] [Related]
24. CCR5 Blockade Suppresses Melanoma Development Through Inhibition of IL-6-Stat3 Pathway via Upregulation of SOCS3.
Tang Q; Jiang J; Liu J
Inflammation; 2015 Dec; 38(6):2049-56. PubMed ID: 26047948
[TBL] [Abstract][Full Text] [Related]
25. Single-Site Nanozymes with a Highly Conjugated Coordination Structure for Antitumor Immunotherapy via Cuproptosis and Cascade-Enhanced T Lymphocyte Activity.
Liu Y; Niu R; Zhao H; Wang Y; Song S; Zhang H; Zhao Y
J Am Chem Soc; 2024 Feb; 146(6):3675-3688. PubMed ID: 38305736
[TBL] [Abstract][Full Text] [Related]
26. Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanisms.
Yu Y; Cho HI; Wang D; Kaosaard K; Anasetti C; Celis E; Yu XZ
J Immunol; 2013 Feb; 190(4):1873-81. PubMed ID: 23315072
[TBL] [Abstract][Full Text] [Related]
27. Acetyl-CoA carboxylase obstructs CD8
Hunt EG; Hurst KE; Riesenberg BP; Kennedy AS; Gandy EJ; Andrews AM; Del Mar Alicea Pauneto C; Ball LE; Wallace ED; Gao P; Meier J; Serody JJ; Coleman MF; Thaxton JE
Cell Metab; 2024 May; 36(5):969-983.e10. PubMed ID: 38490211
[TBL] [Abstract][Full Text] [Related]
28. IL-27 increases the proliferation and effector functions of human naïve CD8+ T lymphocytes and promotes their development into Tc1 cells.
Schneider R; Yaneva T; Beauseigle D; El-Khoury L; Arbour N
Eur J Immunol; 2011 Jan; 41(1):47-59. PubMed ID: 21182076
[TBL] [Abstract][Full Text] [Related]
29. PPARG-mediated ferroptosis in dendritic cells limits antitumor immunity.
Han L; Bai L; Qu C; Dai E; Liu J; Kang R; Zhou D; Tang D; Zhao Y
Biochem Biophys Res Commun; 2021 Oct; 576():33-39. PubMed ID: 34478917
[TBL] [Abstract][Full Text] [Related]
30. Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model.
Molavi O; Ma Z; Hamdy S; Lai R; Lavasanifar A; Samuel J
Immunol Cell Biol; 2008; 86(6):506-14. PubMed ID: 18392040
[TBL] [Abstract][Full Text] [Related]
31. Isolation of adoptively transferred CD8
Xiao L; Yi Q
STAR Protoc; 2023 Mar; 4(1):101945. PubMed ID: 36525345
[TBL] [Abstract][Full Text] [Related]
32. Anticancer Tc9 cells: Long-lived tumor-killing T cells for adoptive therapy.
Lu Y; Wang Q; Yi Q
Oncoimmunology; 2014; 3():e28542. PubMed ID: 25054087
[TBL] [Abstract][Full Text] [Related]
33. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
Kemp RA; Ronchese F
J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
[TBL] [Abstract][Full Text] [Related]
34. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
[TBL] [Abstract][Full Text] [Related]
35. Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11.
Lang X; Green MD; Wang W; Yu J; Choi JE; Jiang L; Liao P; Zhou J; Zhang Q; Dow A; Saripalli AL; Kryczek I; Wei S; Szeliga W; Vatan L; Stone EM; Georgiou G; Cieslik M; Wahl DR; Morgan MA; Chinnaiyan AM; Lawrence TS; Zou W
Cancer Discov; 2019 Dec; 9(12):1673-1685. PubMed ID: 31554642
[TBL] [Abstract][Full Text] [Related]
36. STAT3 signaling contributes to the high effector activities of interleukin-15-derived dendritic cells.
Okada S; Han S; Patel ES; Yang LJ; Chang LJ
Immunol Cell Biol; 2015; 93(5):461-71. PubMed ID: 25582338
[TBL] [Abstract][Full Text] [Related]
37. JAK/STAT3-Regulated Fatty Acid β-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance.
Wang T; Fahrmann JF; Lee H; Li YJ; Tripathi SC; Yue C; Zhang C; Lifshitz V; Song J; Yuan Y; Somlo G; Jandial R; Ann D; Hanash S; Jove R; Yu H
Cell Metab; 2018 Jan; 27(1):136-150.e5. PubMed ID: 29249690
[TBL] [Abstract][Full Text] [Related]
38. CD8
Xu C; Lu X; Liu W; Chen A; Meng G; Zhang H; Li B; Zhang Y; Wu J; Wei J
J Transl Med; 2018 May; 16(1):132. PubMed ID: 29784005
[TBL] [Abstract][Full Text] [Related]
39. Interleukin-35 Suppresses Interleukin-9-Secreting CD4
Zhang Q; Yang L; Liu S; Zhang M; Jin Z
Front Immunol; 2021; 12():645835. PubMed ID: 34177894
[TBL] [Abstract][Full Text] [Related]
40. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
